SAB Biotherapeutics, Inc.

SABS · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Assets
Cash & Equivalents$8,898$56,566$15,047$33,207
Short-Term Investments$11,863$0$0$0
Receivables$55$0$5,557$8,011
Inventory$0$0$0$0
Other Curr. Assets$2,977$2,341$1,494$8,975
Total Curr. Assets$23,792$58,907$22,097$50,192
Property Plant & Equip (Net)$19,921$24,684$28,340$30,949
Goodwill$0$0$0$0
Intangibles$0$0$0$0
Long-Term Investments$0$0$0$0
Tax Assets$0$0$0$0
Other NC Assets$482$350$468$0
Total NC Assets$20,403$25,034$28,807$30,949
Other Assets$0$0$0$0
Total Assets$44,195$83,941$50,905$81,141
Liabilities
Payables$1,695$946$3,679$4,459
Short-Term Debt$812$1,853$1,396$3,100
Tax Payable$0$40$50$216
Deferred Revenue$0$1,322$0$100
Other Curr. Liab.$5,473$6,652$9,868$18,580
Total Curr. Liab.$7,980$10,813$14,993$26,455
LT Debt$3,857$4,054$4,533$5,416
Deferred Rev, NC$0$0$0$0
Deferred Tax Liab, NC$0$0$0$0
Other NC Liab.$6,389$11,774$321$10,720
Total NC Liab.$10,246$15,828$4,853$16,136
Other Liabilities$0$0$0$0
Cap. Leases$3,857$4,856$4,614$6,719
Total Liabilities$18,226$26,642$19,847$42,591
Equity
Pref Stock$0$0$0$0
Common Stock$1$1$5$4
Retained Earnings-$124,169-$90,064-$47,870-$29,129
AOCI-$135$26$0$0
Other Equity$150,273$147,336$78,923$67,675
Total Equity$25,970$57,299$31,058$38,550
Supplemental Information
Minority Interest$0$0$0$0
Total Liab. & Tot. Equity$44,195$83,941$50,905$81,141
Net Debt-$4,229-$50,659-$9,118-$24,691